Reorganization of Outsourced Services for Pharmaceutical Companies and Expansion of Service Offerings

「In collaboration with ITOCHU Corporation (hereinafter, "ITOCHU"), the company began providing "Co-MR," an information-support service that centralizes pharmaceutical companies' MR (medical representative) activities in contact centers.」

「20 July 2022 エイツーヘルスケア株式会社 Sale of shares 1,440」

「As part of its collaborative initiatives, the company began providing a "Device Management Service" jointly with Belong to support remote clinical trials in DCTs (Decentralized Clinical Trials(*)) .」

「In the pharmaceutical business, the company introduced Oracle Corporation's cloud service, "Clinical One Randomization & Supplies Management," to expand its CRO (Contract Research Organization) services through the digitalization of clinical trial processes. This will digitalize operations previously centered on paper-based processes, enabling earlier development of trial designs, flexible changes to settings and timely delivery of investigational drugs, thereby significantly shortening clinical trial timelines.」

「During the first 9 months of the current consolidated fiscal year, as part of efforts to strengthen the healthcare business, which is expected to grow, we began strengthening collaboration among group companies with エイツーヘルスケア株式会社 of the ITOCHU Group, concerning clinical development and sales-support services for pharmaceuticals, medical devices, and other products, with the aim of providing new services to pharmaceutical companies in the new normal era. This will enable us to propose outsourcing services that complete the service flow for clinical trials and post-marketing surveillance of pharmaceuticals, medical devices, and other products on a one-stop basis, reducing the administrative burden on pharmaceutical companies and providing high-quality services through mutual collaboration.」

「In anticipation of the prolonged COVID-19 pandemic, we also began collaborating with Veeva Japan株式会社 to promote the appropriate use of pharmaceuticals through remote detailing, in which medical representatives (MRs), mainly employed by pharmaceutical companies, remotely provide information on pharmaceuticals to physicians and other healthcare professionals, with the aim of supporting a healthcare system adapted to the “new lifestyle.” Through this collaboration, we will develop and begin offering this summer a joint solution that enables the rapid establishment, even during emergencies, of a remote detailing channel for secure communications between healthcare professionals and pharmaceutical companies.」

「On 1 November 2019, we carried out a merger by absorption between consolidated subsidiaries to optimize the allocation of management resources, including personnel and business locations, and establish an efficient group operating structure by integrating the contact center and pharmaceutical and healthcare development-support businesses of ㈱ビーアイメディカル with the CRM business operated by ㈱ベルシステム24 using AI and other new technologies.」

「In the Other business, we transferred the CSO business of our consolidated subsidiary ㈱ビーアイメディカル to IQVIAサービシーズジャパン株式会社, a leading CSO provider, and acquired all shares of ㈱ビーアイメディカル held by ITOCHU Corporation. ㈱ビーアイメディカル entered into an exclusive distribution agreement for MCS Pharma Care Cloud, a pharmaceutical-industry solution provided by エンブレース株式会社 to support the pharmaceutical industry's entry into integrated community care by facilitating communication among healthcare professionals, care workers, patients, and their families, with the aim of strengthening its CRM business for the pharmaceutical sector. We also transferred all shares of ㈱BELL24・Cell Product, which provides SMO services to medical institutions, to サイトサポート・インスティテュート株式会社, a leading SMO provider, and ㈱BELL24・Cell Product ceased to be a consolidated subsidiary.」

「We entered into an agreement to transfer the CSO business of our consolidated subsidiary 株式会社ビーアイメディカル to IQVIAサービシーズジャパン株式会社, a leading CSO provider, and, following the business transfer, entered into a share transfer agreement under which we would acquire from ITOCHU Corporation the shares of ㈱ビーアイメディカル held by ITOCHU Corporation.」

「Although the previous consolidated fiscal year's reorganization contributed revenue from MR dispatch services for pharmaceutical companies, the substantial decline in revenue from the pharmaceutical development-support business resulted in lower revenue than in the previous consolidated fiscal year.」

「In the Other business, we reorganized the business of ㈱ベル・メディカルソリューションズ (currently ㈱ビーアイメディカル), together with ITOCHU Corporation and its subsidiaries, to further strengthen the outsourced services business for pharmaceutical companies. Specifically, effective 1 January 2017, the business of ㈱ベル・メディカルソリューションズ (currently ㈱ビーアイメディカル) was separated into a pharmaceutical development-support business and a business centered on BPO services for pharmaceutical companies. The former was integrated into エイツーヘルスケア株式会社, a wholly owned subsidiary of ITOCHU Corporation that had engaged in the same business, through an absorption-type company split, with エイツーヘルスケア株式会社 as the successor company, while the latter was integrated with IML株式会社, a wholly owned subsidiary of ITOCHU Corporation that provided MR dispatch services and other services for pharmaceutical companies, through a merger by absorption, with ㈱ベル・メディカルソリューションズ (currently ㈱ビーアイメディカル) as the surviving company.」

「On 1 January 2017, for the purpose of further strengthening the outsourced services business for pharmaceutical companies, our wholly owned subsidiary 株式会社ベル・メディカルソリューションズ transferred its pharmaceutical development-support business through an absorption-type company split to エイツーヘルスケア株式会社, a wholly owned subsidiary of ITOCHU Corporation engaged in the same business, and simultaneously absorbed IML株式会社, a wholly owned subsidiary of ITOCHU Corporation that provides MR (Medical Representative) dispatch services for pharmaceutical companies. On the same day, 株式会社ベル・メディカルソリューションズ changed its corporate name to 株式会社ビーアイメディカル.」

「In the Other business, we decided to reorganize the business of our wholly owned subsidiary 株式会社ベル・メディカルソリューションズ (BMS), effective 1 January of the following year, together with ITOCHU Corporation and its subsidiaries, with the aim of further strengthening the contract research organization (CRO) business for pharmaceutical companies. Specifically, the business will be separated into a pharmaceutical development-support business and a business centered on BPO services for pharmaceutical companies. The pharmaceutical development-support business will be absorbed by エイツーヘルスケア株式会社 (A2), a wholly owned subsidiary of ITOCHU Corporation engaged in the same business, while the business centered on BPO services for pharmaceutical companies will absorb IML株式会社 (IML), a wholly owned subsidiary of ITOCHU Corporation that provides MR (Medical Representative) dispatch services and other services for pharmaceutical companies.」